{"id":"W4296530176","doi":"10.1016/s2152-2650(22)01456-2","title":"MPN-375 BET Inhibitor Pelabresib (CPI-0610) Combined With Ruxolitinib in Patients With Myelofibrosis – JAK Inhibitor-Naïe or With Suboptimal Response to Ruxolitinib – Preliminary Data From the MANIFEST Study","year":2022,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Ruxolitinib; Myelofibrosis; Medicine; Clinical endpoint; Internal medicine; Gastroenterology; Anemia; Phases of clinical research; Fibrosis; Extramedullary hematopoiesis; Surgery; Bone marrow; Clinical trial; Haematopoiesis; Stem cell","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001488475,0.0007533543,0.00160129,0.0003213017,0.0002772897,0.00103475,0.0004594723,0.000451494,0.001693511],"category_scores_gemma":[0.001033442,0.0003122875,0.001256881,0.0004373647,0.0003614725,0.0008099388,0.0002977236,0.00177012,0.0004375212],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009203321,"about_ca_system_score_gemma":0.0007483321,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001146986,"about_ca_topic_score_gemma":0.006021218,"domain_scores_codex":[0.9995086,0.0002137462,0.00004149357,0.00007333679,0.00006363061,0.00009923054],"domain_scores_gemma":[0.999437,0.0001321523,0.0001320304,0.00005904099,0.00003409238,0.0002057222],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.5306374,0.01733363,0.1100761,0.001120567,0.006694301,0.0007694597,0.0002746138,0.002752998,0.02880646,0.0004406303,0.008649721,0.2924441],"study_design_scores_gemma":[0.2693241,0.2477393,0.4437692,0.0002350202,0.007389462,0.00164952,0.000394135,0.004070802,0.005623279,0.0009517378,0.01872867,0.0001247791],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9887665,0.006739901,0.000279911,0.0006286531,0.000124539,0.0002130176,0.0006888461,0.00005168297,0.002506829],"genre_scores_gemma":[0.9946383,0.001957781,0.0003870776,0.0004956003,0.0001263532,0.0001001849,0.001497887,0.000009590948,0.0007873602],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001693511,"threshold_uncertainty_score":0.007871926,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05084599366323148,"score_gpt":0.3320740202494757,"score_spread":0.2812280265862442,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}